COL9A1 supplies the alpha1 chain of fibril-associated collagen IX. The structural interpretation combines native human cartilage cross-links, chain assembly and matrix localization. It does not treat the chain as an enzyme or as an autonomous major fibrillar scaffold. A GO:0030020 structural core is retained with type IX trimer membership and extracellular matrix organization; the GO definition expressly permits extracellular collagen proteins under this structural term.
The three official products reconstruct exactly from the recorded sequence changes: long P20849-1 is 921 residues, Short P20849-2 is 678 residues, and truncated P20849-3 is 328 residues. The short product lacks NC4 but retains the main downstream assembly regions. The truncated product retains NC4 and part of COL3, but lacks the remaining collagenous and noncollagenous assembly regions. A retained domain establishes sequence coverage, not secretion, folding or equivalent intact-product activity.
Original human cartilage analysis maps alpha1(IX) collagenous-region cross-links to alpha1(II) and alpha3(IX) NC1. These are positive network contacts, not an independently established alpha1–alpha1 homodimer. The separate original recombinant study reports predominantly monomers and dimers when human full-length alpha1(IX) is individually expressed in insect cells. That supports non-core contextual self-association while preserving the original source assertion. Its engineered shortened constructs must not be renamed as the natural Short product. The source-evidence index, followup_source_clarifications, provides a short exact Results excerpt and Figure 3 caption locator, distinguishing original full-text evidence from the selected abstract cache. PMID:8660302(https://pubmed.ncbi.nlm.nih.gov/8660302/), original indexed source, PMID:17880280 accepted postprint.
The NC2 structure uses the three IX chains attached to engineered type-I host–guest collagen sequences. It resolves a genuine assembly interface and stagger, without being an intact IX structure or testing every natural product. The gene/exon study's complete abstract corroborates identity and transcript architecture; full original assembly passages were unavailable. PMID:27897211(https://doi.org/10.1038/srep37831), PMID:9707347(https://pubmed.ncbi.nlm.nih.gov/9707347/).
Original PMID:15047691 directly tests human NC4 residues 24–268 with rat COMP (P35444, including its 266–755 fragment), heparin, competition and a folding-controlled basic-region mutation. Thus extracellular matrix binding and heparin binding are justified source-preserving replacements. They are semantic ligand refinements, not claims of current typed descendant edges from the original generic terms. The 17553797 abstract independently supports the heparin-tetrasaccharide interaction and reports positive zinc measurements. Full Methods/control access remained unavailable, so no zinc NEW or physiological zinc-regulatory core is proposed. Heparin binding is also represented as a distinct core activity of alpha1 NC4 in extracellular matrix. The original 2004 SPR and solid-state assays tested both isolated NC4 and full-length recombinant human collagen IX. The apparent full-molecule affinity was 3.6 nM, versus approximately 0.6 µM for isolated NC4; this is not a sub-nanomolar measurement. Additional heterotrimer binding sites are not all assigned to alpha1, and a native matrix-bridging mechanism or natural splice-product equivalence is not inferred. 15047691 original Methods/Results, 17553797 primary abstract.
Recombinant human NC4 performs direct inhibitory work in the terminal-complement assays: purified C9 polymerization and membrane-associated polymeric C9 decrease with controls. This supports one experimental, NC4-scoped NEW GO:0001971. The domain is not itself a factor-I cofactor or protease. It enhances reactions containing FH/C4BP, and a poorly NC4-binding C4BP mutant retains enhancement; an obligatory cofactor-bridging model is therefore not asserted. Effects of intact collagen IX and quantitative endogenous fragment activity remain unresolved. Human pAM104-2 identity is established by the original indexed Methods of reference16, PMID:19700767, without assuming equivalence to the earlier pGAT2-NC23 construct or exact residue endpoints. 21659506 full source, 19700767.
Current GO:0001971 includes inhibition of MAC assembly/formation and has no narrower returned descendant. Final is_a/part_of coverage against all original, replacement and core terms finds no ancestor/descendant redundancy. CLU has two exact human IDA records for this term; VTN and COMP have no matching records in complete queries, which is retained as an absence rather than a universal exclusion. These are annotation comparators, not newly read comparator experiments. The broader parent and a redundant complement-binding NEW are omitted. The saved GO-CAM index has no COL9A1/P20849 hit.
The entire original PMID:3473493, pp4044–4048, is chicken embryonic cartilage sequence/genomic and fragment work. It genuinely studies alpha1/alpha2 NC3 differences but supplies no organ-morphogenesis experiment or traceable organ-development statement. The TAS process assertion is source-scoped over-annotation, without denying that matrix structure can participate in development. The reference's MISCITED assessment is limited to that process attribution. The original page 4044 Materials and methods explicitly identifies the chicken embryo sternal-cartilage preparation; the source-evidence index links the page image and a short exact excerpt.
The electronic assertion is distinct. Current ARBA00028067 branch83 has the exact FunFam 2.60.120.200:FF:000105 found in the official target record. The corrected projection supersedes an initial projection that omitted FunFam evaluation. The transfer's biological specificity remains unresolved; a current matching branch does not expose its historical training premise, and the separate 1987 TAS paper does not settle the whole rule. Current ARBA00028691 has a verified InterPro/Primates match supporting precursor ER-lumen context. 3473493.
Exact sequence/ROGID joins retain three positive yeast-screen records each for GIPC1-2, CRYAA and the KLK6 precursor. GIPC1 remains generic non-core binding; verified CRYAA chaperone and KLK6 protease classes support more specific binding terms, without a folding/catalytic activity claim for COL9A1 or a mature-state/interface claim. The COL6A1 pair has two positive AP-MS records in HEK293T/HCT116 contexts, one spoke-expanded. Collagen binding narrows the verified partner class while preserving this co-complex scope. The current GO:0051087 definition names binding a chaperone partner; it does not require that this pair perform client folding or share an established native compartment. The campaign instruction permits a supported partner-class refinement while preserving the assay limits. Neither mammalian validation elsewhere in the Y2H dataset nor generic affinity purification is described as a pair-specific purified binary assay. 32814053, 33961781.
All 82 IBA donor joins were checked against official identity mappings and 293 distinct literal current records. Historical ancestral placements were not reconstructed; PTN source-status uncertainty is separated from independently supported target actions. Target self-inclusion is legitimate descendant evidence, not circularity. Electronic source values and inert qualifier fields remain unchanged.
Nine actual Reactome summaries and 171 typed participant paths distinguish extracellular secretion output, ER-luminal precursor input, matrix cross-links and ligand-set membership. Other participants' catalytic functions and generalized procollagen prose are not transferred to COL9A1. Broad extracellular-region terms retain the source event compartments, including secreted precursors; the independently supported extracellular-matrix locations describe the matrix-associated product. Current GO:0062023 is obsolete and is not introduced as a replacement. Underlying event citations were not all independently recovered.
Human ECM proteomics supplies two exact original supplementary target rows (row121, complete and matrisome sheets). The entry is labeled Isoform Short with principal P20849-2, but lists additional grouped accessions. It supports grouped extracellular detection, not isoform-exclusive peptide/activity resolution or a direct tensile-force measurement. 25037231.
Selected source artifacts remain unchanged. External original text, page images and genuine fresh full-text variants are tracked separately; selected abstract status is not equated with external full access. Full original 17553797 and 9707347 remained unavailable. For 19700767, a complete normal abstract and a specific original indexed Methods window were read, not the complete article. The selected 33961781 partial source is supplemented by a separately archived genuine normal full-text read. The source-evidence file records definitions, exact joins, source locators and access summaries.
The genuine Falcon attempt timed out at90 seconds, and the configured perplexity-lite fallback returned401 insufficient_quota. No provider report was fabricated. These notes and the source-specific review are the manual research record.
Ordinary validation, derived-status checking and HTML rendering pass. The ordinary updater derives DRAFT because validation retains advisories; no annotation is PENDING. Two advisories are retained deliberately: supported generic GIPC1 binding follows the campaign exception, and the morphogenesis TAS and ARBA assertions have distinct evidence and judgments. The source-evidence index records aggregate primary quote totals across the authored outputs, including its two short external-only source excerpts.